Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00695123 · ClinicalTrials.gov registry record

Screening for Subjects to Participate in Studies of Blood Disorders

A clinical trial, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Completed
Registry status
816
Enrollment target

NCT00695123 is a clinical trial that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 816 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00695123 has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

COMPLETED
Registry status
816 participants
Enrollment target

Study Summary

This study will determine eligibility for participation in research studies on blood disorders conducted by the National Heart, Lung and Blood Institute and the National Institute of Diabetes, Digestive, and Kidney Diseases. Healthy volunteers, patients with blood disorders under study by NHLBI and NIDDK and potential stem cell donors for patients with blood disorders who are 8 years of age and older may be eligible for this screening protocol. (Healthy volunteers who qualify for research protocols would serve as control subjects.) Participants undergo the following tests and procedures: Healthy Volunteers * Medical history, physical examination, blood tests and urine sample collection. * Buccal mucosa sample collection. (Cells are collected from the inside of the cheek by gentle scraping with a bristly brush.) * Bone marrow aspiration (only for volunteers 18 years of age and older). Potential Stem Cell Donor -Same as for healthy volunteers plus evaluations that may include electrocardiogram, echocardiogram, imaging studies (X-rays, CT scans, MRI scans and others), heart evaluation, and lung function tests. Patient with Blood Disorder * Same as for stem cell donors plus additional evaluations and treatments that may include radiation oncology evaluation, catheter placement, blood transfusions, kidney and liver biopsies. Short courses of drug treatment for induction of fetal hemoglobin in sickle cell patients, and/or iron chelation in patients receiving chronic red cell transfusions may be included as well.

Trial Details

FieldValue
Enrollment Target 816 participants
Start Date 2008-07-03
Est. Completion 2021-04-02

What the Registry Record Tells You About NCT00695123

The ClinicalTrials.gov registry entry for NCT00695123 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 816 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00695123 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00695123 about?

NCT00695123 is a clinical study titled "Screening for Subjects to Participate in Studies of Blood Disorders". This study will determine eligibility for participation in research studies on blood disorders conducted by the National Heart, Lung and Blood Institute and the National Institute of Diabetes, Digestive, and Kidney Diseases. Healthy volunteers, patients with blood disorders under study by NHLBI and...

What is the current status of trial NCT00695123?

This trial is currently completed. The enrollment target is 816 participants. The study started on 2008-07-03. Estimated completion is 2021-04-02.

Who is sponsoring clinical trial NCT00695123?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.